 |
160 Products |  |
813 Diseases | | 160 Products |
|
1552 Trials |  |
75151 News |  |
| «12...2728293031323334353637...858859» |
- Neulasta (pegfilgrastim) / Roche
STEM CELL MOBILIZATION STRATEGY WITH PEGILGRASTIM FOR STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A DIRECT COST COMPARISON (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_612;
pegfilgrastim resulted in overall lower costs per mobilization strategy, given maximum expenditure per medication unit that is provided from the CMED table. This value difference might differ significantly over actual values practiced over large purchases, for example.
- Prolia (denosumab) / Amgen
Evaluation of the safety and efficacy of Denosumab in patients with multiple myeloma and severe renal impairment (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_565;
Possibly 60 mg, monthly, is sufficient for these patients to prevent both SREs and hypocalcemia. However, further prospective research with larger cohort and longer follow-up period will confirm these results and refine treatment guidelines.
- Prolia (denosumab) / Amgen
Approach to Diagnosis and Management of multiple myeloma-related bone disease in Latin America, a GELAMM survey. (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_442;
There are still centers that use x-ray examinations, an approach that, although no longer recommended, remains the only accessible method in some parts of the region. A large majority of physicians in LA use ARD, with zoledronic acid being the most frequent.
- Sequencing of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma (Exhibit Hall, Pavilion 3) - Sep 26, 2024 - Abstract #IMW2024IMW_379;
A large majority of physicians in LA use ARD, with zoledronic acid being the most frequent. To date, 3 BsAB have been approved for RRMM, two of which
- | oprozomib (ONX 0912) / Amgen
Phase classification, Combination therapy: INTREPID-1: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 26, 2024
P1, N=61, Completed, Sponsor: Amgen
To date, 3 BsAB have been approved for RRMM, two of which Phase classification: P1b --> P1
- | Ibrance (palbociclib) / Pfizer, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Trial completion date, Trial primary completion date: Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 26, 2024
P1/2, N=36, Completed, Sponsor: Sudipto Mukherjee, MD, PhD, MPH
Phase classification: P1b --> P1 Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2024 | Trial primary completion date: Jun 2024 --> Jan 2024
- ||| Ibrance (palbociclib) / Pfizer, taselisib (GDC-0032) / Roche, pictilisib (GDC-0941) / Roche
Trial completion, Combination therapy: PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (clinicaltrials.gov) - Sep 26, 2024
P1, N=79, Completed, Sponsor: Royal Marsden NHS Foundation Trust
Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2024 | Trial primary completion date: Jun 2024 --> Jan 2024 Unknown status --> Completed
- | hydroxyurea / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: ACHiEvE-SCD: Hydroxyurea and EPO in Sickle Cell Disease (clinicaltrials.gov) - Sep 25, 2024
P1/2, N=17, Active, not recruiting, Sponsor: Julia Xu
Unknown status --> Completed Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: May 2025 --> Dec 2024
- || Nplate (romiplostim) / Amgen
New P2 trial: Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia (clinicaltrials.gov) - Sep 25, 2024
P2, N=48, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | Repatha (evolocumab) / Amgen, Astellas
Journal, Real-world evidence, Real-world: Real-World Clinical Profile of Patients Prescribed Evolocumab in Japan. (Pubmed Central) - Sep 25, 2024
Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: May 2025 --> Dec 2024 This study provides real-world insights into evolocumab utilization in Japan for optimizing patient care and adherence to guideline-based therapies to better address hypercholesterolemia in Japan.
- | Herceptin (trastuzumab) / Roche
Journal: Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States. (Pubmed Central) - Sep 25, 2024
Trastuzumab biosimilars utilization has grown since their introduction to the US market. Exploration of these biosimilars' comparative effectiveness and safety to their reference product is warranted.
- | Enbrel (etanercept) / Pfizer, Amgen
Journal: Case report: Breaking CNS immuno-privilege: TNF?-inhibitor triggers aseptic meningitis in a patient with rheumatoid arthritis. (Pubmed Central) - Sep 25, 2024
Here we report the case of a patient, affected by RA and treated with etanercept, who suddenly developed focal neurological symptoms. Cerebrospinal fluid, magnetic resonance imaging (MRI), and positron emission tomography (PET)/MRI findings are reported and support the diagnosis of TNF-?i -associated aseptic meningitis.
- || Ibrance (palbociclib) / Pfizer
Review, Journal, HEOR, Metastases: A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. (Pubmed Central) - Sep 25, 2024
Findings were also consistent across key clinical characteristics (visceral metastases, neutropenia), as well as patient populations often underrepresented in clinical trials (Asian patients, older adults). Overall, current evidence suggests that HRQoL is largely preserved with the addition of palbociclib to endocrine therapy in patients with HR+/HER2- aBC or mBC across study types and populations.
- || Stivarga (regorafenib) / Bayer
Review, Journal: Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. (Pubmed Central) - Sep 25, 2024
One of the primary factors restricting regorafenib's clinical utilization and combination therapy is its toxicity reactions. To optimize regorafenib treatment regimens, it is especially important to further understand the specific toxicity mechanisms of regorafenib as a multi-kinase inhibitor.
- || Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Review, Journal: Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials. (Pubmed Central) - Sep 25, 2024
To optimize regorafenib treatment regimens, it is especially important to further understand the specific toxicity mechanisms of regorafenib as a multi-kinase inhibitor. By revealing their structure-activity relationships, pharmacological actions, and clinical trials, small-molecule drugs can offer broad prospects for the development of new medications.
- | fludarabine IV / Generic mfg., busulfan / Generic mfg., sorafenib / Generic mfg.
Trial completion date, Trial primary completion date: NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - Sep 25, 2024
P1/2, N=74, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
By revealing their structure-activity relationships, pharmacological actions, and clinical trials, small-molecule drugs can offer broad prospects for the development of new medications. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- Tavneos (avacopan) / Amgen
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3658;
ADVOCATE was a double-blind, double-dummy, active-controlled trial, with patients randomized 1:1 to receive avacopan (30 mg twice daily) or a prednisone taper (60 mg/day tapered to 0 by week 21) on a background of cyclophosphamide (followed by azathioprine or mycophenolate mofetil) or rituximab. Findings from this post hoc subgroup analysis of ADVOCATE in patients with GPA or MPA without kidney involvement at study baseline demonstrate that avacopan was associated with a numerically higher rate of sustained remission, lower relapse rate, lower GC-related toxicity, greater improvements in HRQoL, and similar safety vs a prednisone taper.
- Tavneos (avacopan) / Amgen
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3656;
Findings from this post hoc subgroup analysis of ADVOCATE in patients with GPA or MPA and active ENT manifestations at baseline showed that avacopan was associated with faster resolution of ENT manifestations, higher rate of sustained remission, lower relapse rate, lower GC-related toxicity, greater improvement in HRQoL, and similar safety vs a prednisone taper. These data indicate avacopan may be efficacious in patients with ENT involvement of GPA or MPA.
- Tavneos (avacopan) / Amgen
General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3655;
P3
These data indicate avacopan may be efficacious in patients with ENT involvement of GPA or MPA. In the ADVOCATE trial, treatment with either avacopan or a prednisone taper was associated with the reversal of nearly all active general, nervous system, mucous membranes/eyes, and skin manifestations of GPA or MPA.
- Tavneos (avacopan) / Amgen
Efficacy and Safety of Avacopan over 12 Months in Japanese Patients with MPA/GPA: A Single-center Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3653;
On the other hand, avacopan-induced liver injury should be noted. The results also suggested that avacopan have a small effect on the decrease in serum MPO-ANCA levels.
- Tavneos (avacopan) / Amgen
Real-World Use of Avacopan for ANCA-Associated Vasculitis Beyond 52 Weeks (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3652;
Rituximab was used alongside AVP for remission maintenance in majority of patients. Infection complications were the most observed adverse effects.
- Tavneos (avacopan) / Amgen
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3650;
Infection complications were the most observed adverse effects. Our findings suggest a potential association between the absence of glucocorticoid use concomitant with avacopan and DILI associated with avacopan.
- Tavneos (avacopan) / Amgen
Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3648;
Most patients with 6 and 12 months of follow-up continued avacopan use over the respective periods. Future studies will assess outcomes following treatment with avacopan in a real-world setting.
- Tavneos (avacopan) / Amgen
Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3647;
A large proportion of users, overall and across kidney, ENT, and pulmonary subgroups, discontinued GCs by month 5 and achieved complete remission. Among those with kidney involvement, significant reductions in proteinuria and improvement in the eGFR were observed by month 6.
- Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT) (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3587;
P2
Conditioning chemoradiation was then administered per an IRB-approved individual treatment plan (Patients 1-3) or per our clinical trial NCT03630211 (Patients 4-7) with rituximab, ATG, total body irradiation 600 cGy with lung and kidney shielding, and cyclophosphamide or thiotepa +/- alemtuzumab... Among our cohort of refractory jSSc patients with moderate to severe disease, ASCT was a safe and effective intervention that provided sustained global disease modifying improvement up to 4 years after transplant with benefit seen as early as 3 months for all patients.
- Prolia (denosumab) / Amgen
The Risk of Medication-related Osteonecrosis of the Jaw (MRONJ) in a Patient with Osteoporosis Treated with Antiresorptive Therapy and Undergoing Dental Care Is Negligible with a CTX Threshold Above 260 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3531;
This is the first meta-analysis evaluating the risk of medication-related osteonecrosis of the jaw (MRONJ) based on serum CTX levels before ongoing dental care. For patients undergoing oral bisphosphonate treatment for osteoporosis, a threshold of 260 pg/mL is linked to an almost negligible risk (beyond the 99th percentile) of experiencing MRONJ.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3526;
Clinical FRAX should be considered in patients without recent DXA. Developing population health tools to improve monitoring in this population remains challenging as many data domains in GIOP care require chart validation (true GC use vs.
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Disability, Functional Limitation, and Use of Anti-fracture Drug Therapies in a Cohort of 3651 U.S. Adults with Osteogenesis Imperfecta (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3513;
Anti-fracture drug use increased with age; but, the prevalence of medication use remained low in adults with both mild and severe OI phenotypes. These data provide a unique understanding of anti-fracture drug utilization in adults with OI.
- Prolia (denosumab) / Amgen
Fractures Post Lung Transplant: A Retrospective Cohort Study Conducted at an International Transplant Center (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3511;
Denosumab is a safe and effective medication post-LT and it is associated with a 65% reduction in the odds of having a post-LT OP fracture. This is a novel finding among post-LT patients and has not been demonstrated elsewhere.
- Prolia (denosumab) / Amgen
Generation of a Human 3D Bone Model to Mimic Glucocorticoid- induced Osteoporosis In Vitro (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3509;
Ultimately, we obtained an in vitro 3D co-culture of osteoblasts and osteoclasts simulating human native bone capable of mimicking key aspects of GIOP in vitro via treatment with methylprednisolone. As a proof of concept, GIOP was treated with established antiresorptive drugs showing an increase of osteogenesis markers.
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3505;
After one year of treatment, the T-scores of the lumbar spine and femoral neck increased significantly. Not a single case of MACE nor any other safety issues were detected.
- Prolia (denosumab) / Amgen
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta. (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3503;
Nearly all have a history of previous fractures and demonstrate BMD within the range of osteoporosis. The most commonly used treatments are bisphosphonates, being the predominant choices pamidronate in pediatric cases and zoledronic acid in adults.
- Prolia (denosumab) / Amgen
Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3501;
-Adherence to anti-osteoporotic treatment is insufficient. Long-term follow-up is required to monitor adherence to anti-osteoporotic treatment and avoid refractures.
- daxdilimab (HZN-7734) / Amgen
Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3463;
P2
Long-term follow-up is required to monitor adherence to anti-osteoporotic treatment and avoid refractures. The primary endpoint was the proportion of pts achieving a British Isles Lupus Assessment Group 2004 Index
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3355;
These results suggest that tezepelumab may be effective in the treatment of patients with EGPA and refractory or relapsing asthma and/or ENT manifestations and may allow GC sparing. The safety profile appeared to be favorable, with no risk of drug-associated eosinophilia.
- Tavneos (avacopan) / Amgen
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3350;
In ADVOCATE, patients with newly-diagnosed GPA or MPA had GT-SNAPSHOT scores similar to those with relapsing disease, indicating comparable baseline GC-related toxicity. However, the affected GC toxicity domains differed between groups, with GC toxicities associated with chronic GC exposure more commonly seen among patients with relapsing disease and GC toxicities that can develop more rapidly more commonly seen in those with newly-diagnosed disease.
- Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3349;
The GC-sparing benefits would be most notable in people at highest risk of relapse (e.g., PR3-ANCA positivity). These findings highlight the importance of GC-sparing strategies and the need for studies that identify people most likely to benefit.
- Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3343;
These findings highlight the importance of GC-sparing strategies and the need for studies that identify people most likely to benefit. Participants were grouped based on the timing of their enrollment in the cohort, using three separate periods: (A) April 2006
- Tavneos (avacopan) / Amgen
Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3337;
The addition of avacopan to rituximab or cyclophosphamide for treatment of GPA or MPA does not appear to impact ANCA levels. The lack of correlation between ANCA levels and outcome of treatment in the ADVOCATE trial suggests that ANCA levels are an unreliable marker of treatment response.
- Tavneos (avacopan) / Amgen
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA) (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3328;
The glucocorticoid-sparing oral C5aR antagonist avacopan improves disease control and recovery of renal function in GPA and MPA [3,4]... Low concentrations of circulating anti-C5aR aabs reflect an increased risk for relapse in EGPA, comparable to that previously reported in GPA and MPA [5].
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3293;
The first AT has a longer survival and better efficacy when compared to subsequent lines. Clinicians tend to switch the first line therapy earlier since 2010, likely due to a shift towards a treat to target approach and more available therapeutic options.
- Ibrance (palbociclib) / Pfizer
Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE) (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2996;
P3
This work enhances our understanding of molecular predictors for severe SLE flares in the context of clinical trials. The findings also suggest potential new pathways for targeted treatment strategies.
- Krystexxa (pegloticase) / Amgen
Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2994;
P4
In MIRROR RCT, stability persisted through Month 12 with and without MTX co-therapy. Importantly, 28.3% of patients had elevated Fib-4 at baseline; these subjects also had Fib-4 stability through Wk 52 of treatment.
- Tavneos (avacopan) / Amgen
Blood Transcriptome Analysis Reveals Enhanced B Cell and Complement Cascade Signatures in Patients with Major Neuropsychiatric Systemic Lupus Erythematosus (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2989;
Upregulation of the adaptive immune response and complement activation is strongly associated with neuropsychiatric involvement in SLE. This suggests that inhibitors of the complement cascade, such as avacopan, and B cell-targeted therapies, like CD19 CAR T cell therapy
- AMG 329 / Amgen
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2912;
The PK profile of AMG 329 is consistent with a typical mAb. Reductions in pDCs, cDCs and monocytes were observed that lasted up to 12 weeks following the highest dose in the MAD cohort.
- Blincyto (blinatumomab) / Astellas, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2895;
Treatment with bispecific T-cell engagers had a favorable safety profile in 12 patients with refractory autoimmune disease. Hence, targeting CD19 or BCMA with T cell engagers appears feasible in autoimmune disease and warrants further clinical development.
- Olumiant (baricitinib) / Eli Lilly, Enbrel (etanercept) / Pfizer, Amgen
A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2709;
Hence, targeting CD19 or BCMA with T cell engagers appears feasible in autoimmune disease and warrants further clinical development. MSKUS-determined response to baricitinib/baricitinib + MTX was non-inferior to that of etanercept + MTX.
- Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2671;
MSKUS-determined response to baricitinib/baricitinib + MTX was non-inferior to that of etanercept + MTX. The focus was on the association of MACE
- Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2669;
Despite high vaccination rates, vaccinated individuals had a higher incidence of COVID-19, likely due to other factors. Specific immunotherapies such as abatacept (7.1%) and mycophenolate (6.5%) were associated with higher mortality rates, emphasizing the need for careful monitoring.
- Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Novartis, Repatha (evolocumab) / Amgen, Astellas
Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_2639;
Future research should investigate the underlying mechanisms driving this increased risk and evaluate long-term safety across diverse populations. Clinically, monitoring for IBD symptoms in patients receiving inclisiran is recommended to ensure timely intervention and management.